CD274 and non-small cell lung carcinoma: The results showed that the ORR (45.3%) of nivolumab combined with ipilimumab in first-line treatment of NSCLC was higher than that of chemotherapy alone (26.9%), and the mPFS of nivolumab combined with ipilimumab and chemotherapy alone was 7.2 months versus 5.5 months (p < 0.001), mOS was 17.1 months versus 14.9 months (p = 0.007), and was independent of the expression level of PD-L1 17.